Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

66.00 +0.67 (+1.03%)
Streaming Delayed Price Updated: 11:35 AM EDT, Jul 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
3 Monster Stocks in the Making to Buy Right Now
Via The Motley Fool
Independent Bank Posts Upbeat Earnings, Joins Blaize Holdings, Interactive Brokers Group And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
3 Monster Stocks to Hold for the Next 10 Years
These companies have compelling long-term futures, but the coming decade could prove particularly exciting as each one comes into its own. 
Via The Motley Fool
CRISPR Stock Surges in Recent Weeks: What's Going On?
Via Benzinga
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via Investor Brand Network
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
10 Monster Stocks to Hold for the Next 10 Years
Each of these 10 businesses offers a market-leading product or service within an industry that's set to explode. 
Via The Motley Fool
Cathie Wood-Led Ark Launches Buffer ETFs For Its Flagship ARKK, Analyst Says It's Like Diet Soda — 50% Loss Protection, But There's A Catch
Cathie Wood's Ark Investment Management has filed plans to launch four new exchange-traded funds designed to offer downside protection for investors in its flagship ARK Innovation ETF (BATS: ARKK),... 
Via Benzinga
Topics ETFs
2 Beaten-Down Stocks With Massive Upside Potential
Via The Motley Fool
2 Growth Stocks to Buy Hand Over Fist in July
These companies are poised to produce fireworks for your portfolio over the coming years. 
Via The Motley Fool
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Via The Motley Fool
44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy
The 2025 TIME 100 Most Influential Companies list includes over 40 companies that investors can buy stock in. 
Via Benzinga
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research 
Via Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
Via Benzinga
Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
Via Investor's Business Daily
Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It
Cathie Wood is bullish on biotech companies using gene sequencing, AI, and CRISPR tech to cure previously untreatable diseases. 
Via Benzinga
Topics Artificial Intelligence
The Best Stocks to Invest $1,000 in Right Now
Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to bear more fruit. 
Via The Motley Fool
Topics Government World Trade
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
Via The Motley Fool
Topics Economy
5 Monster Stocks to Hold for the Next 10 Years
These companies are just starting to realize the potential in up-and-coming fields, like AI and gene editing. 
Via The Motley Fool
Topics Artificial Intelligence
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?
Via The Motley Fool
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years
Via The Motley Fool
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
CRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholders 
Via MarketBeat
Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?
Via The Motley Fool
2 Biotech Stocks That Are Screaming Buys in May
Via The Motley Fool
Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire?
The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline. 
Via The Motley Fool
3 Monster Stocks to Hold for the Next 10 Years
The planets are lining up for these three stocks' underlying companies. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
In a rising market, the iconic growth investor is adding to positions trading well below their earlier highs. 
Via The Motley Fool
Topics Artificial Intelligence World Trade
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst
CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.